AI Driven Discovery Viva Biotech's AI driven drug discovery platform and collaboration with NVIDIA positions them as an AI first partner for complex programs; opportunities include co development, access to GPU accelerated workflows, and AI assisted modeling to accelerate lead identification for difficult targets.

End to End One stop services from early stage structure based drug R and D to commercial manufacturing through Langhua Pharma; target pharma and biotech clients seeking a single partner to streamline discovery, CMC, and regulatory readiness, reducing vendor fragmentation and cycle time.

Startup Partnerships Equity for service model appeals to high potential startups; sales approach includes forming strategic collaborations with venture backed companies needing discovery capacity with potential for future licensing or manufacturing milestones.

Advanced Platform Advantage Viva offers a suite of advanced platforms including V DEL technology platform, X ray crystallization, cryo EM, HDX, SPR, ASMS, and CADD to tackle challenging targets; ideal for clients pursuing biologics or multi target programs and seeking comprehensive screening and validation.

Growth Momentum Significant funding and revenue momentum indicate capacity to scale collaborations; use as credibility to engage large pharma and global biotechs seeking a reliable CRO with integrated discovery and manufacturing capabilities.